Therapeutic efficacy and safety of PCSK9-monoclonal antibodies on familial hypercholesterolemia and statin-intolerant patients: A meta-analysis of 15 randomized controlled trials

Proprotein convertase subtilisin/kexin9 monoclonal antibodies (PCSK9-mAb) have been studied intensively to identify their effect in lowering levels of low density lipoprotein cholesterol (LDL-C). However, the applicable target of PCSK9-mAbs remains inconclusive so far. Therefore, this first meta-ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Qian, Li Jun, Gao, Yao, Zhang, Yan Mei, Chu, Ming, Yao, Jing, Xu, Di
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428249/
https://www.ncbi.nlm.nih.gov/pubmed/28331223
http://dx.doi.org/10.1038/s41598-017-00316-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5428249/
https://www.ncbi.nlm.nih.gov/pubmed/28331223
http://dx.doi.org/10.1038/s41598-017-00316-3

Ejemplares similares